Exelixis, Inc. has reported subgroup results from the Phase 3 CABINET pivotal trial showing that CABOMETYX, the cabozantinib tablet, improved progression-free survival versus placebo in patients with previously treated advanced neuroendocrine tumors regardless of whether their tumors were functional or non-functional. The data, presented at the American Society of Clinical Oncology 2026 Annual Meeting, add a clinically relevant layer to the already approved role of cabozantinib in well-differentiated pancreatic and extra-pancreatic neuroendocrine tumors.
Why does the functional versus non-functional split matter in advanced neuroendocrine tumor treatment?
The importance of the CABINET subgroup analysis is not simply that cabozantinib worked across another slice of the trial population. The more useful signal is that Exelixis now has evidence across a clinically awkward divide in neuroendocrine tumor care, where tumor biology, symptom burden and treatment goals do not always line up cleanly. Non-functional neuroendocrine tumors are often managed around tumor growth and metastatic progression, while functional neuroendocrine tumors add the complication of hormone release, which can produce symptoms such as diarrhea, flushing and blood pressure instability.
That distinction matters because clinicians do not treat progression-free survival as an abstract endpoint in this setting. In advanced neuroendocrine tumors, delaying progression may preserve treatment optionality, postpone the need for another systemic therapy and help maintain disease control in a patient population that can live for years with metastatic disease but eventually becomes refractory. A therapy that appears to retain activity across both functional and non-functional disease can therefore carry practical value in sequencing decisions, particularly after prior systemic treatment.
The limitation is that subgroup analyses rarely settle clinical debates on their own. The CABINET trial was pivotal, randomized, double-blinded and placebo-controlled, which gives the dataset weight. However, the functional neuroendocrine tumor subgroup was smaller than the non-functional subgroup, meaning clinicians will still look closely at confidence intervals, adverse event management and real-world tolerability before treating the subgroup data as equivalent to a standalone definitive study. The signal is useful, but it is not the same as a dedicated trial designed only around functional disease.
What does the CABINET subgroup analysis change for cabozantinib’s position after prior therapy?
The subgroup data strengthen the argument that cabozantinib is not merely an option for a narrow biological segment of advanced neuroendocrine tumors. In non-functional neuroendocrine tumors, cabozantinib reduced the risk of disease progression or death by 74 percent versus placebo, with median progression-free survival of 9.4 months compared with 3.1 months. In functional neuroendocrine tumors, cabozantinib reduced the risk by 60 percent, with median progression-free survival of 12.7 months compared with 5.4 months.
Those figures matter because previously treated advanced neuroendocrine tumor care remains a sequencing puzzle rather than a single dominant pathway. Somatostatin analogs, everolimus, sunitinib in pancreatic disease, chemotherapy in selected patients, liver-directed approaches and peptide receptor radionuclide therapy all occupy roles depending on tumor site, grade, receptor expression, pace of progression and symptom burden. Cabozantinib’s value proposition is clearest where clinicians need an oral targeted therapy that can delay radiographic progression after earlier options have been exhausted or are no longer suitable.
The unresolved question is whether stronger subgroup confidence translates into broader and earlier use. Progression-free survival benefit can support adoption, but the practical decision still depends on toxicity, patient frailty, disease tempo and the clinician’s view of how cabozantinib should be sequenced against established targeted and radionuclide options. The CABINET data make cabozantinib harder to overlook, but they do not remove the complexity of choosing the right patient at the right time.
How should clinicians weigh efficacy against toxicity in a chronic oncology setting?
Cabozantinib’s safety profile in the functional and non-functional neuroendocrine tumor subgroups was consistent with its known profile, and no new safety signals were identified. That is important because cabozantinib is already a familiar multi-kinase inhibitor across renal cell carcinoma, hepatocellular carcinoma, differentiated thyroid cancer and now neuroendocrine tumors. Familiarity can lower the barrier to adoption because oncologists already understand the need for blood pressure monitoring, dose modifications and management of gastrointestinal and fatigue-related adverse events.
However, neuroendocrine tumors present a different tolerability equation from some faster-moving cancers. Many patients with advanced well-differentiated disease may have a long treatment journey, which means toxicity is not simply a short-term hurdle. In the subgroup analysis, common grade 3 or 4 adverse events included hypertension and diarrhea in functional disease, and hypertension and fatigue in non-functional disease. These are manageable in many patients, but they are not trivial, especially in functional tumors where diarrhea or blood pressure issues may already be part of the disease burden.
This is where the data become clinically nuanced. A strong progression-free survival benefit is valuable, but the net benefit depends on whether patients can remain on treatment long enough to gain that disease control without unacceptable quality-of-life trade-offs. Dose reductions, treatment interruptions and proactive supportive care may become central to real-world use. For industry observers, the commercial success of cabozantinib in this indication will depend not only on the label and trial statistics, but also on whether clinicians view its toxicity management as predictable enough for a heterogeneous NET population.
Why could CABINET influence treatment sequencing even after regulatory approvals?
The U.S. and European approvals of cabozantinib in previously treated advanced neuroendocrine tumors already established the regulatory basis for use. The CABINET subgroup analysis adds a different kind of value by helping define how broadly clinicians may interpret the benefit across patient profiles. Regulatory approval tells the market a drug can be used. Subgroup evidence helps clinicians decide when they feel confident using it.
This distinction is particularly relevant in neuroendocrine tumors because disease location and behavior vary widely. Pancreatic neuroendocrine tumors are often treated differently from extra-pancreatic disease, and functional status adds another layer to treatment planning. By showing activity in both functional and non-functional populations, CABINET may reduce hesitation among clinicians who might otherwise wonder whether a growth-factor pathway inhibitor is better suited to one group than the other.
The risk is that subgroup data can be overread. The analysis does not necessarily prove cabozantinib improves hormone-related symptoms in functional neuroendocrine tumors, even if it delays progression. For functional disease, symptom control remains a central clinical objective, and tumor stabilization does not always equal rapid hormonal improvement. Clinicians will likely watch for real-world evidence, additional analyses and patient-reported outcomes to understand whether disease control translates into broader clinical benefit beyond imaging-based progression-free survival.
What does this mean for Exelixis as cabozantinib faces franchise maturity questions?
For Exelixis, the data reinforce the strategic importance of extending cabozantinib’s lifecycle through tumor-specific evidence rather than relying only on legacy commercial strength. Cabozantinib is the U.S.-based oncology firm’s flagship product, and neuroendocrine tumors give the medicine another approved setting where an oral targeted therapy can address a defined unmet need. In a market where oncology companies are under pressure to defend mature franchises, incremental but clinically credible label expansion can still matter.
Investor sentiment around Exelixis is shaped by a familiar biotech tension. The oncology firm has a revenue-generating anchor in cabozantinib, but it also needs to show that its pipeline can reduce dependence on a single commercial engine over time. CABINET supports the durability of cabozantinib’s role, while the firm’s next-generation kinase inhibitor zanzalintinib is being evaluated in the STELLAR-311 pivotal trial against everolimus in an earlier treatment-line setting for advanced neuroendocrine tumors. That creates a two-track strategy: defend the existing franchise while trying to move a newer asset into a more competitive position.
The stock context reflects cautious confidence rather than runaway enthusiasm. Exelixis shares recently traded around $50.48, with a market capitalization of about $13.49 billion and a price-to-earnings ratio near 16.7. That valuation suggests investors already assign meaningful value to the commercial base, but the next rerating catalyst may require evidence that neuroendocrine tumor expansion, zanzalintinib development or broader pipeline execution can create growth beyond cabozantinib’s established indications.
How does cabozantinib compare with the broader neuroendocrine tumor treatment landscape?
Cabozantinib competes in a treatment landscape that is fragmented by design. Neuroendocrine tumors differ by primary site, receptor profile, grade, growth pace and hormone secretion. That makes the market less about one drug displacing every other option and more about whether a therapy earns a reliable place in the sequence. Everolimus remains an important oral targeted therapy, peptide receptor radionuclide therapy has reshaped care for selected somatostatin receptor-positive disease, and site-specific approaches continue to matter.
The CABINET findings position cabozantinib as a meaningful oral option after progression on prior therapy, particularly because the study included both pancreatic and extra-pancreatic neuroendocrine tumor cohorts and used blinded independent central review for progression-free survival. That trial design strength matters in a disease where progression can be slow and assessment consistency is important. A placebo-controlled trial in a previously treated population gives clinicians a clearer estimate of treatment effect than uncontrolled datasets would.
The commercial challenge is that sequencing decisions in neuroendocrine tumors are influenced by practice patterns and institutional experience. Some clinicians may favor peptide receptor radionuclide therapy earlier where receptor status supports it, while others may use oral targeted therapies based on comorbidities, logistics, access and patient preference. Cabozantinib’s opportunity lies in becoming a dependable option across those scenarios, but its adoption will depend on how comfortably physicians balance efficacy, tolerability and available alternatives.
What should regulators, clinicians and industry observers watch after ASCO 2026?
The next phase of interest will move beyond whether cabozantinib can delay progression in advanced neuroendocrine tumors. That question is increasingly well supported. The more important questions now concern durability of use, patient selection, symptom outcomes in functional disease and how cabozantinib performs in real-world sequencing after somatostatin analogs, targeted therapy or peptide receptor radionuclide therapy.
Regulatory watchers are unlikely to view the subgroup analysis as a standalone regulatory inflection point because approvals are already in place in key markets. However, the data can still influence label confidence, guideline discussion and physician education. In oncology markets, the difference between being approved and being routinely selected is often built through exactly this type of evidence layering, especially when a disease is biologically diverse and treatment choices are not linear.
For Exelixis, the broader strategic question is whether the cabozantinib franchise can serve as both a commercial base and a bridge to the next pipeline chapter. CABINET keeps cabozantinib clinically relevant in another hard-to-treat oncology niche, but it also raises expectations for the next asset. If zanzalintinib can show a differentiated profile in earlier-line advanced neuroendocrine tumors, Exelixis could deepen its position in the category. If not, the firm may still have a stronger cabozantinib story, but the market will keep asking how much growth remains in a franchise that has already done much of the heavy lifting.
The neutral reading is that CABINET’s subgroup analysis is not a dramatic reinvention of neuroendocrine tumor care. It is more important than that in practical terms. It gives clinicians a stronger reason to view cabozantinib as a broadly applicable disease-control option across functional and non-functional advanced neuroendocrine tumors, while leaving the most commercially important questions to be answered by real-world use, sequencing studies and the next wave of Exelixis pipeline data.
Can Exelixis defend its oncology franchise with deeper CABINET evidence? added by Pallavi Madhiraju on
View all posts by Pallavi Madhiraju →